Drug Guidance for Subsidy 17/02/2025 Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combinati... See all × 17/02/2025 Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combination with tremelimumab for inclusion on the MOH List of Subsidised Drugs for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy. The decision for durvalumab in combination with tremelimumab was based on its unfavourable cost effectiveness versus sorafenib, its uncertain clinical and cost effectiveness versus atezolizumab plus bevacizumab, and the unacceptable price-volume agreements proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for durvalumab plus tremelimumab are provided in the Annex.
INTRAVENOUS Select a brand starting with the letter: I IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML [SIN16845P]